BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Consistent with our studies, it has been reported that disrupting the BCR-ABL/JAK2-STAT5 network eliminates BCR-ABL-transduced cells and primitive CD34+ CML cells; JAK2 inhibitors have been shown to sensitize CML cells to TKIs in the BM microenvironment [42-44].